science
Health Canada Approves Needle-Free Epinephrine Nasal Spray Neffy for Severe Allergic Reactions
Health Canada has approved Neffy, the first needle-free epinephrine treatment for severe allergic reactions, as a nasal spray. ALK Canada purchased rights to distribute the two-milligram dose for adults and children weighing at least 30 kilograms. The product could reach the market this summer.
Apr 15, 4:11 PM·1m read1 source
Substrate placeholder — needs reviewAudio version
Tap play to generate a narrated version.
in Canada Health Canada approved Neffy, the first needle-free epinephrine treatment for severe allergic reactions, on April 15, 2026.
The approval covers a nasal spray version of the drug. ALK Canada purchased the rights to distribute Neffy in the country. The Neffy treatment consists of a two-milligram dose approved for adults and pediatric patients who weigh at least 30 kilograms.
That weight is roughly 66 pounds. The product is pocket-sized and has a shelf life of 30 months from its time of manufacture. ALK Canada stated the Neffy spray could be on the market as soon as this summer.
Neffy was approved for use in the United States in summer 2024. In the United States, Neffy is available in a one-milligram dose for kids who weigh 15 to 30 kilograms. The one-milligram dose of Neffy has not been approved in Canada.
auto-injectors known by the brand name EpiPen are the only emergency treatment option available for allergic reactions.
EpiPens are single-use, pre-filled devices used to shoot a dose of epinephrine into the muscle.
Canada, a Toronto-based non-profit organization, applauded the approval of the two-milligram Neffy treatment as 'an important step forward' that gives Canadians more choices.
